<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451516</url>
  </required_header>
  <id_info>
    <org_study_id>2006000925</org_study_id>
    <nct_id>NCT00451516</nct_id>
  </id_info>
  <brief_title>St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety</brief_title>
  <official_title>St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating&#xD;
      anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety&#xD;
      commonly occurs, it is conceivable that a combination of an established antidepressant agent&#xD;
      such as SJW and an established anxiolytic agent such as kava may effectively treat MDD&#xD;
      presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may&#xD;
      also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid&#xD;
      anxiety, than by the individual substances alone. Determination of this is not addressed in&#xD;
      this study due to limitations of time and resources. The determination of the strength of the&#xD;
      SJW-kava combination will be ascertained by comparing similar trials using SJW and kava&#xD;
      mono-therapy in addressing MDD and GAD.&#xD;
&#xD;
      The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid&#xD;
      anxiety more than placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BDI II</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>BAI</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>DASS</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHOQOL</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Mood Monitoring Form</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <condition>Anxiety Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herbal medicine (St. John's wort and Kava)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Any person male or female aged 18-65 presenting with a diagnosis of unipolar&#xD;
             depression confirmed by CIDI auto (quantified by BDI) and an anxiety score on the DASS&#xD;
             of 8 or above i.e. the mean (quantified also by BAI)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Psychotic/ Bipolar illness&#xD;
&#xD;
          -  Current or &lt; 6 month significant suicidal ideation&#xD;
&#xD;
          -  Diagnosed hepato-biliary disease/inflammation&#xD;
&#xD;
          -  Current or &lt; 6 month substance abuse disorder including alcohol&#xD;
&#xD;
          -  Current or &lt; 12 month use of kava, St. John's wort,&#xD;
&#xD;
          -  Current or &lt; 1 month of synthetic antidepressants or benzodiazepines&#xD;
&#xD;
          -  Previous reaction to kava or St. John's wort&#xD;
&#xD;
          -  Medications that maybe pharmacokinetically altered via St. John's wort including:&#xD;
&#xD;
               -  Amitriptyline anti-coagulants e.g. phenprocoumon, warfarin,&#xD;
&#xD;
               -  Anti-fugals e.g. voriconazole,&#xD;
&#xD;
               -  Anti-histamines e.g. fexofenadine,&#xD;
&#xD;
               -  Benzodiazepines e.g. alprazolam,&#xD;
&#xD;
               -  Chemotherapeutics e.g. irinotecan, digoxin, HIV medication (anti-retrovirals), *&#xD;
                  Immunosuppressants e.g. cyclosporine, methadone, OCP,&#xD;
&#xD;
               -  Statins e.g. simvastatin, warfarin (Henderson 2002; Izzo 2004).&#xD;
&#xD;
               -  However this interactions are based on case studies and theoretical interactions&#xD;
                  and are regarded to be induced by hyperforin (a constituent of St. John's wort);&#xD;
                  low or non-standardised hyperforin preparations are regarded to not induce drug&#xD;
                  interactions as little induction of P-glycoprotein and CYP P450 enzymes occurs&#xD;
                  (Madabushi et al. 2006). Although in vitro studies have confirmed that kava and&#xD;
                  the isolated kavalactones modulate certain CYP 450 enzymes, no documented&#xD;
                  evidence of human kava-drug pharmacokinetic interactions exists (Mathews,&#xD;
                  Etheridge &amp; Black 2002; Singh 2005)&#xD;
&#xD;
          -  Seeing a psychologist or counsellor currently or in the previous month.&#xD;
&#xD;
          -  Non-English speakers.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome Sarris, BHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RBWH</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2008</last_update_posted>
  <keyword>Plant, medicine</keyword>
  <keyword>Psychiatry</keyword>
  <keyword>Major depressive disorder</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Major Depressive Disorder with comorbid anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

